Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Chemotherapy Induced Anemia Overview | 8 | 1 |
| Therapeutics Development | 9 | 1 |
| Pipeline Products for Chemotherapy Induced Anemia Overview | 9 | 1 |
| Chemotherapy Induced Anemia Therapeutics under Development by Companies | 10 | 2 |
| Chemotherapy Induced Anemia Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Chemotherapy Induced Anemia Products under Development by Companies | 15 | 1 |
| Chemotherapy Induced Anemia Companies Involved in Therapeutics Development | 16 | 14 |
| 3SBio Inc. | 16 | 1 |
| BIOCAD | 17 | 1 |
| Chong Kun Dang Pharmaceutical Corp. | 18 | 1 |
| Dr. Reddy's Laboratories Limited | 19 | 1 |
| Galenica Ltd. | 20 | 1 |
| Panacea Biotec Limited | 21 | 1 |
| Pfizer Inc. | 22 | 1 |
| PharmaEssentia Corporation | 23 | 1 |
| PhytoHealth Corporation | 24 | 1 |
| Pieris Pharmaceuticals Inc | 25 | 1 |
| Sandoz International GmbH | 26 | 1 |
| SBI Pharmaceuticals Co., Ltd. | 27 | 1 |
| Therapure Biopharma Inc. | 28 | 1 |
| Tolero Pharmaceuticals, Inc. | 29 | 1 |
| Chemotherapy Induced Anemia Therapeutics Assessment | 30 | 10 |
| Assessment by Monotherapy Products | 30 | 1 |
| Assessment by Combination Products | 31 | 1 |
| Assessment by Target | 32 | 2 |
| Assessment by Mechanism of Action | 34 | 2 |
| Assessment by Route of Administration | 36 | 2 |
| Assessment by Molecule Type | 38 | 2 |
| Drug Profiles | 40 | 23 |
| (aminolevulinic acid hydrochloride + sodium ferrous citrate) Drug Profile | 40 | 2 |
| darbepoetin alfa Drug Profile | 42 | 1 |
| darbepoetin alfa Drug Profile | 43 | 1 |
| darbepoetin alfa Drug Profile | 44 | 1 |
| darbepoetin alfa Drug Profile | 45 | 1 |
| darbepoetin alfa Drug Profile | 46 | 1 |
| epoetin alfa Drug Profile | 47 | 2 |
| epoetin zeta Drug Profile | 49 | 3 |
| ferric carboxymaltose Drug Profile | 52 | 2 |
| P-1116 Drug Profile | 54 | 1 |
| PHN-013 Drug Profile | 55 | 1 |
| PRS-080 Drug Profile | 56 | 2 |
| SSS-06 Drug Profile | 58 | 1 |
| TBI-304H Drug Profile | 59 | 1 |
| TP-0184 Drug Profile | 60 | 1 |
| TP-0413 Drug Profile | 61 | 1 |
| TXA-302 Drug Profile | 62 | 1 |
| Chemotherapy Induced Anemia Dormant Projects | 63 | 1 |
| Chemotherapy Induced Anemia Discontinued Products | 64 | 1 |
| Chemotherapy Induced Anemia Product Development Milestones | 65 | 5 |
| Featured News &Press Releases | 65 | 1 |
| Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H | 65 | 1 |
| Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia | 65 | 1 |
| Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health | 65 | 1 |
| Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology | 66 | 1 |
| Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting | 66 | 1 |
| Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology | 67 | 1 |
| Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended | 67 | 1 |
| Aug 09, 2010: Dr Reddy s Launches Darbepoetin Alfa For Treatment Of Anemia In India | 68 | 1 |
| Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world s first complex biosimilar | 68 | 1 |
| Jan 07, 2008: Sandoz and Gambro form strategic alliance | 69 | 1 |
| Aug 31, 2007: European Commission approves Sandoz's epoetin alfa Binocrit | 69 | 1 |
| Appendix | 70 | 2 |
| Methodology | 70 | 1 |
| Coverage | 70 | 1 |
| Secondary Research | 70 | 1 |
| Primary Research | 70 | 1 |
| Expert Panel Validation | 70 | 1 |
| Contact Us | 70 | 1 |
| Disclaimer | 71 | 1 |